Highlights of $BMY's pipeline

Betting that will consolidate after crossing $46

**Bristol Myers Squibb (BMS)** has been busy advancing their pipeline, and they've got some intriguing developments. Imagine a bunch of scientists in lab coats doing a happy dance—I'm pretty sure that's happening at BMS right now. Here's the scoop:

1. **Doubling Down on Registrational Assets**: BMS plans to **double the number of registrational assets** over the next 18 months—from six to a whopping twelve! These are the heavy hitters—the ones that are marching toward regulatory approval. 🚀

2. **Cell Therapy Magic**: Brace yourself for some alphabet soup: They've got a CD19-directed **NEX T cell therapy** (that's like the Avengers of immune cells) called BMS-986353. It's not just a mouthful; it's also expanding into clinical trials for immunologic diseases, including severe, refractory systemic lupus erythematosus. Say that three times fast! 🌪️

3. **CAR T Awesomeness**: BMS is also cooking up a **potential first cell therapy** that targets GPRC5D. It goes by the snappy name **BMS-986393**. This little warrior is strapping on its armor and starting a registrational trial in relapsed/refractory multiple myeloma (RRMM). 🛡️

4. **BCMA x CD3 Tango**: Picture this: a dance floor, disco lights, and two partners—the BCMA protein and the CD3 T-cell. They're doing the tango, and it's called **alnuctumab**. This dynamic duo is advancing into a Phase 3 trial for—you guessed it—RRMM. 💃🕺

5. **Protein Degradation Drama**: BMS is introducing a potential game-changer: **golcadomide**, a first-in-class protein degrader. It's like the Marie Kondo of cancer treatment—tidying up large B-cell lymphoma. This one's moving into a Phase 3 trial, and I bet it's sparking joy in the lab. 🌿

6. **Androgen Receptor De-grabber**: Okay, that's not the official name, but close! BMS has an androgen receptor degrader (fancy science-speak for "let's dismantle this thing") that's strutting into pivotal studies in metastatic castration-resistant prostate cancer. 🕶️

So, in a nutshell, BMS is jazzed about their pipeline. They're like the Elon Musk of drug development—bold, ambitious, and ready to change lives. 🌎💙

Is there anything else you'd like to know? Maybe a fun fact about lab rats or the secret handshake of pharmaceutical CEOs? 😉

Source: Conversation with Copilot, 7/24/2024
(1) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... news.bms.com/news/corporate-financial/2023/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day/default.aspx.
(2) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... finance.yahoo.com/news/bristol-myers-squibb-highlights-advancing-123000365.html.
(3) Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated .... businesswire.com/news/home/20230914789335/en/Bristol-Myers-Squibb-Highlights-Advancing-Pipeline-and-Differentiated-Research-Platforms-to-Support-Long-Term-Sustainable-Growth-at-RD-Day.
(4) Bristol Myers Squibb - Bristol Myers Squibb Reports Fourth Quarter and .... news.bms.com/news/details/2024/Bristol-Myers-Squibb-Reports-Fourth-Quarter-and-Full-Year-Financial-Results-for-2023/default.aspx.

註釋